KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesChange in Working CapitalExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Change in Taxes (2020 - 2025)

Historic Change in Taxes for Novartis Ag (NVS) over the last 6 years, with Q4 2025 value amounting to -$814.0 million.

  • Novartis Ag's Change in Taxes fell 7505.38% to -$814.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.4 billion, marking a year-over-year decrease of 4021.16%. This contributed to the annual value of -$2.4 billion for FY2025, which is 4021.16% down from last year.
  • Per Novartis Ag's latest filing, its Change in Taxes stood at -$814.0 million for Q4 2025, which was down 7505.38% from -$266.0 million recorded in Q3 2025.
  • Novartis Ag's Change in Taxes' 5-year high stood at $261.0 million during Q4 2023, with a 5-year trough of -$814.0 million in Q4 2025.
  • For the 5-year period, Novartis Ag's Change in Taxes averaged around -$403.2 million, with its median value being -$422.0 million (2023).
  • As far as peak fluctuations go, Novartis Ag's Change in Taxes skyrocketed by 20275.59% in 2023, and later tumbled by 41282.05% in 2024.
  • Novartis Ag's Change in Taxes (Quarter) stood at -$645.0 million in 2021, then soared by 60.62% to -$254.0 million in 2022, then soared by 202.76% to $261.0 million in 2023, then plummeted by 278.16% to -$465.0 million in 2024, then tumbled by 75.05% to -$814.0 million in 2025.
  • Its Change in Taxes stands at -$814.0 million for Q4 2025, versus -$266.0 million for Q3 2025 and -$507.0 million for Q2 2025.